Loratadin Vim Spectrum relieves symptoms associated with allergic rhinitis (e.g. hay fever), such as: sneezing, abundant nasal discharge or itching of the nose, burning or itching of the eyes.
Loratadin Vim Spectrum can also be used to reduce the symptoms of hives (itching, redness, as well as the number and size of rashes on the skin).
The improvement of these manifestations is maintained for the entire period of the day and helps you resume your usual daily activities and sleep. Composition: Loratadine 10mg and excipients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, colloidal anhydrous silicon dioxide, talc.
Composition: Loratadine 10mg and excipients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, colloidal anhydrous silicon dioxide, talc.
Method of administration:
Oral administration. The tablets can be taken without connection to the meal schedule.
Adults and children over 12 years of age: The recommended dose is 10 mg of loratadine once daily. The tablet can be taken without connection to the timing of meals.
Children aged 6 to 12 years and weighing more than 30 kg: the recommended dose is 10 mg loratadine once a day.
Children aged 6 to 12 years and weighing less than 30 kg: the recommended dose is 5 mg loratadine once a day.
For children aged 2 to 6 years, age-appropriate dosage forms are recommended. The safety and efficacy of loratadine have not been established in children below 2 years of age.
Precautions:
Patients with severe hepatic impairment should be given a lower starting dose as they may have lower loratadine clearance. A starting dose of 10 mg loratadine every other day is indicated for adults and children weighing more than 30 kg, aged 6 to 12 years.
For children weighing less than 30 kg and aged 6 to 12 years, the recommended starting dose is 5 mg loratadine every other day.
No dose adjustment is necessary in patients with renal impairment.
No dose adjustment is required in the elderly.
For children under 12 years of age, other pharmaceutical forms are recommended.
Teratogenic effects of loratadine have not been demonstrated in studies in rats and rabbits at doses of 96 mg/kg (75 and 150 times the maximum recommended daily human dose in mg/m2, respectively). There are no adequate studies in humans. Because animal studies on reproductive effects are not always predictive of effects in humans,Loratadine should not be administered during pregnancy until careful assessment of the potential foetal risk/maternal benefit ratio.
Loratadine and its metabolite decarboethoxyloratadine are excreted in human milk, achieving concentrations equal to those of the body. During breastfeeding, depending on the importance of the therapy for the mother, either loratadine treatment or breastfeeding should be interrupted.
Presentation form: 10 tablets
Reviews
There are no reviews yet.